Skip to main content

Table 1 Descriptive characteristics of invasive breast cancer cases and matched controls

From: Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model

 

Cases (n = 1762)

Controls (n = 1890)

Cohort, n

 BGS

230

230

 CLUE II

87

87

 CSB

69

69

 Guernsey

124

124

 NHS

93

93

 NHS II

248

250

 NSMSC

31

31

 NYUWHS

493

496

 ORDET

214

224

 Sister

173

286

Age at blood donation, years, n (%)

 35–40

472 (26.8)

487 (25.8)

 41–45

708 (40.2)

752 (39.8)

 46–50a

582 (33.0)

651 (34.5)

Race/ethnicity, n (%)

 White

1587 (90.1)

1696 (89.7)

 Black/African American

76 (4.3)

73 (3.9)

 Other or missing

99 (5.6)

121 (6.4)

Age at diagnosis, years, n (%)

 35–45

287 (16.3)

 

 46–50

579 (32.9)

 

 51–55

436 (24.7)

 

 56–60

235 (13.3)

 

 61–65

141 (8.0)

 

 > 65

84 (4.8)

 

Lag time between blood donation and diagnosis, years, n (%)

 0–2

274 (15.6)

 

 3–5

420 (23.8)

 

 6–10

443 (25.1)

 

 11–15

286 (16.2)

 

 16–20

201 (11.4)

 

 > 20

138 (7.8)

 

Age at menarche, years, n (%)

 < 12

376 (21.3)

411 (21.7)

 12–13

976 (55.4)

1012 (53.5)

 ≥14 or missingb

410 (23.3)

467 (24.7)

Age at first live birth, years, n (%)

 < 20 or missingb

114 (6.5)

143 (7.6)

 20–24

457 (25.9)

521 (27.6)

 25–29c

473 (26.8)

511 (27.1)

 ≥ 30

304 (17.3)

307 (16.2)

 Nulliparous

414 (23.5)

408 (21.5)

Number of benign breast biopsies, n (%)

 0 or missingb

1339 (76.0)

1559 (82.5)

 ≥ 1

423 (24.0)

331 (17.5)

 0

1311 (74.4)

1415 (74.9)

 1d

382 (21.7)

412 (21.8)

 > 1d

69 (3.9)

63 (3.3)

BMI, kg/m2, n (%)

 < 25

1097 (59.9)

1124 (62.6)

 25–29

420 (24.8)

465 (24.0)

 ≥ 30

234 (15.4)

289 (13.4)

 Missing

11

12

AMH cohort-specific quartiles, n(%)

 Q1

365 (20.7)

480 (25.4)

 Q2

444 (25.1)

468 (24.8)

 Q3

453 (25.7)

468 (24.8)

 Q4

500 (28.4)

474 (25.1)

Testosterone cohort-specific quartiles, n (%)

 Q1

423 (24.0)

511 (27.0)

 Q2

414 (23.5)

464 (24.6)

 Q3

452 (25.7)

460 (24.3)

 Q4

473 (26.8)

455 (24.1)

BCRAT 5-year risk score (%), n (%)e

 < 0.6%

296 (16.8)

332 (17.6)

 0.6–0.99%

679 (38.5)

765 (40.5)

 1–1.66%

525 (29.8)

517 (27.3)

 1.67–1.99%

110 (6.2)

130 (6.9)

 2–2.99%

115 (6.5)

115 (6.1)

 ≥ 3%

37 (2.1)

31 (1.6)

 ER status, n (%)

 ER-positive

1139 (79.8)

 

 ER-negative

289 (20.2)

 

 Unknown

334

 
  1. Note: Cases and controls were matched 1:1 for all cohorts except for Sister Study which matched 1:2
  2. aAll cases had age at blood donation ≤ 50, though for 24 sets, matched controls ages were ≤ 51.2 years at blood donation
  3. bTo be consistent with BCRAT, which imputes missing data to the lowest risk category, we imputed missing data as follows: age at menarche: ≥ 14 for 35 cases (1.5%) and 49 controls (1.9%); age at first live birth: < 20 for 5 cases (0.2%) and 7 (0.3%) controls; number of breast biopsies: 0 for 42 cases (1.8%) and 40 controls (1.6%)
  4. cAs done in BCRAT, nulliparous and women who were 25–29 at first birth were combined in all models
  5. dThe number of first-degree family members with breast cancer was coded as 0, 1, or > 1 affected relatives. For cohorts that collected family history as a no/yes variable, “yes” answers were assigned to the intermediate category (1 affected relative)
  6. eCalculated using the following variables: race, age at menarche, age at first live birth, number of breast biopsies, and number of first-degree family members with breast cancer, history of atypical hyperplasia was missing for all cohorts and set to “no.” Gail model 2 rates and parameters were used as described in [14]
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us